Olr714 inhibitors represent a fascinating and intricate class of chemical compounds with a distinctive mode of action centered around the inhibition of the Olr714 receptor, a member of the olfactory receptor family. Olr714, part of the G protein-coupled receptor (GPCR) superfamily, is primarily involved in the detection of odor molecules, playing a crucial role in the olfactory signaling pathway. These inhibitors are designed to bind selectively to the Olr714 receptor, thereby obstructing its normal function. The precise interaction typically involves binding to the active site or allosteric sites of the receptor, preventing the receptor from undergoing the conformational changes necessary for signaling. This can result in altered olfactory perceptions, providing a unique tool for studying the molecular mechanisms of olfaction.
From a chemical standpoint, Olr714 inhibitors exhibit a diverse range of structures, often characterized by complex aromatic systems, heterocyclic moieties, and various functional groups that enhance their binding affinity and specificity. The synthesis of these inhibitors requires advanced organic chemistry techniques, often involving multiple steps of selective functionalization, protection-deprotection strategies, and careful stereochemical control to achieve the desired molecular configuration. Analytical techniques such as nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), and X-ray crystallography are extensively employed to confirm the structural integrity and purity of these compounds. Additionally, computational modeling and molecular docking studies play a crucial role in understanding the binding interactions and optimizing the design of more potent and selective inhibitors. This chemical diversity not only highlights the synthetic challenges but also underscores the potential of these compounds as powerful molecular probes for dissecting the intricate signaling pathways mediated by the Olr714 receptor.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $182.00 $661.00 $1690.00 | 3 | |
Inhibits multiple tyrosine kinases, potentially affecting angiogenesis and growth factor signaling. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
CDK4/6 inhibitor, potentially impacting cell cycle regulation proteins. | ||||||
Bicalutamide | 90357-06-5 | sc-202976 sc-202976A | 100 mg 500 mg | $42.00 $146.00 | 27 | |
Androgen receptor antagonist, potentially affecting proteins in androgen receptor signaling pathways. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $175.00 $983.00 | 2 | |
BCR-ABL and tyrosine kinase inhibitor, potentially affecting proteins in leukemia signaling pathways. | ||||||
Acalabrutinib | 1420477-60-6 | sc-507392 | 250 mg | $255.00 | ||
Bruton's tyrosine kinase inhibitor, potentially impacting proteins in B-cell receptor signaling pathways. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Multi-kinase inhibitor, potentially affecting proteins in angiogenesis, oncogenesis, and the tumor microenvironment. | ||||||
Abiraterone | 154229-19-3 | sc-460288 | 10 mg | $276.00 | ||
CYP17 inhibitor, potentially affecting steroid synthesis and related signaling pathways. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Inhibits VEGFR, EGFR, and RET tyrosine kinases, potentially affecting proteins in associated signaling pathways. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Bruton's tyrosine kinase inhibitor, potentially impacting proteins in B-cell receptor signaling pathways. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
PARP inhibitor, potentially disrupting DNA repair pathways and affecting protein function. | ||||||